Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for BGB-45035 (IRAK4 Degrader) in Rheumatoid Arthritis. The expected timing is based on the latest available company guidance and may change.
02/26/26:- Phase 1/2 trial in rheumatoid arthritis projected to deliver data readout in H2 2026. 05/06/26:- PR No update. 08/05/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.